Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Lineage Cell Therapeutics, Inc.
Study CP35A008 is a Phase 1, multi-center long term follow-up (LTFU) study for five (5) subjects with complete thoracic SCI that were administered 2 million GRNOPC1 cells in the main study CP35A007. The purpose of this study is to monitor long-term safety in subjects for 15 years post GRNOPC1 administration.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects who received administration of GRNOPC1 under clinical study protocol CP35A007.
Clareo Health | LTFU Study of Subjects Who Received GRNOPC1
